343 related articles for article (PubMed ID: 19489685)
1. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
[TBL] [Abstract][Full Text] [Related]
2. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839
[TBL] [Abstract][Full Text] [Related]
3. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
4. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA
Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670
[TBL] [Abstract][Full Text] [Related]
5. [Detection of DD3 mRNA in the urine of prostate cancer patients and its clinical significance].
Liu GX; Guo HQ; Li XG; Gan WD; Zeng LQ; Shi HL; Zhang SW; Liu TS
Zhonghua Nan Ke Xue; 2007 Jun; 13(6):511-3. PubMed ID: 17615974
[TBL] [Abstract][Full Text] [Related]
6. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
7. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
[TBL] [Abstract][Full Text] [Related]
8. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
[TBL] [Abstract][Full Text] [Related]
9. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
[TBL] [Abstract][Full Text] [Related]
10. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
12. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
Floriano-Sánchez E; Cárdenas-Rodríguez N; Castro-Marín M; Alvarez-Grave P; Lara-Padilla E
Clin Invest Med; 2009 Dec; 32(6):E258. PubMed ID: 20003831
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
[TBL] [Abstract][Full Text] [Related]
14. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
16. PCA3: from basic molecular science to the clinical lab.
Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
[TBL] [Abstract][Full Text] [Related]
17. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.
Sokoll LJ; Ellis W; Lange P; Noteboom J; Elliott DJ; Deras IL; Blase A; Koo S; Sarno M; Rittenhouse H; Groskopf J; Vessella RL
Clin Chim Acta; 2008 Mar; 389(1-2):1-6. PubMed ID: 18061575
[TBL] [Abstract][Full Text] [Related]
18. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
19. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers MJ; van Bokhoven A; Verhaegh GW; Smit FP; Karthaus HF; Schalken JA; Debruyne FM; Ru N; Isaacs WB
Cancer Res; 1999 Dec; 59(23):5975-9. PubMed ID: 10606244
[TBL] [Abstract][Full Text] [Related]
20. Is DD3 a new prostate-specific gene?
Gandini O; Luci L; Stigliano A; Lucera R; Di Silverio F; Toscano V; Cardillo MR
Anticancer Res; 2003; 23(1A):305-8. PubMed ID: 12680228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
